Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BFRI by emailGet an email when BFRI pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BFRI, unsubscribe in one click. Privacy
📣 What BFRI Says Is Next
fourth quarter · “Biofrontera expects to report final, complete fourth quarter and full year financial results for 2025 in March 2026.”
Company press release, Jan 13, 2026 · SEC filing
fourth quarter · “The Company expects to report complete fourth quarter and full year 2025 financial results in March 2026.”
Company press release, Jan 13, 2026 · SEC filing
fourth quarter · “Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass. (January 13, 2026) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025.”
Company press release, Jan 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full BFRI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BFRI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.